Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.018 EUR | -2.12% | -5.21% | -20.96% |
Mar. 14 | Abionyx Pharma: to benefit from a 1ME grant from Bpifrance | CF |
Mar. 11 | Abionyx: reduced net loss in 2023 | CF |
Sales 2023 | 4.6M 4.94M | Sales 2024 * | 4.6M 4.94M | Capitalization | 33.49M 35.94M |
---|---|---|---|---|---|
Net income 2023 | -3M -3.22M | Net income 2024 * | -6M -6.44M | EV / Sales 2023 | 9.02 x |
Net cash position 2023 * | 100K 107K | Net cash position 2024 * | 3.4M 3.65M | EV / Sales 2024 * | 6.54 x |
P/E ratio 2023 * |
-7.43
x | P/E ratio 2024 * |
-6.93
x | Employees | 63 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 77.63% |
1 day | -2.12% | ||
1 week | -5.21% | ||
Current month | +3.88% | ||
1 month | +10.05% | ||
3 months | -18.17% | ||
6 months | -15.87% | ||
Current year | -20.96% |
Managers | Title | Age | Since |
---|---|---|---|
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 06-12-31 |
Director of Finance/CFO | - | 08-04-30 | |
Renee Benghozi
CTO | Chief Tech/Sci/R&D Officer | - | 15-02-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Olivier Martinez
BRD | Director/Board Member | 54 | - |
Christian Chavy
BRD | Director/Board Member | 75 | 15-02-05 |
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 06-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 1.018 | -2.12% | 21 326 |
24-04-24 | 1.04 | -1.52% | 22,531 |
24-04-23 | 1.056 | +0.57% | 21,214 |
24-04-22 | 1.05 | -2.23% | 20,382 |
24-04-19 | 1.074 | 0.00% | 48,974 |
Real-time Euronext Paris, April 25, 2024 at 11:20 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-20.96% | 35.79M | |
-2.00% | 104B | |
+1.85% | 97.42B | |
+0.79% | 22.2B | |
-17.73% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-15.84% | 15.06B | |
+4.03% | 13.98B | |
+35.05% | 11.66B |
- Stock Market
- Equities
- ABNX Stock